Alpha Cognition Presents ZUNVEYL's Data in Toronto
Alpha Cognition, a biopharma company advancing treatments for neurodegenerative diseases, will unveil new clinical data on its lead therapy, ZUNVEYL, at the Alzheimer’s Association International Conference (AAIC) in Toronto, July 27–31, 2025. Dr. Denis Kay, Chief Scientific Officer of Alpha Cognition states,“We are excited to present data demonstrating ZUNVEYL’s bioequivalence and dose proportionality,” 
Alpha Cognition Presents ZUNVEYL's Data in Toronto